Xencor (XNCR) investor relations material

Executive summary

• Reported a net loss of $128.9 million for Q1 2026, compared to $48.4 million in Q1 2025, driven by lower revenues and higher operating expenses.

• Total revenue decreased to $4.5 million from $32.7 million year-over-year, primarily due to reduced milestone and royalty revenue from collaboration agreements and a one-time $6.6 million royalty reduction.

• Pipeline includes five clinical-stage XmAb drug candidates in oncology and autoimmune diseases, with multiple ongoing Phase 1 and 2 studies and key data readouts expected in 2H26 and 3Q26.

• Strategic portfolio management continues, with decisions to advance, partner, or discontinue programs based on clinical data.

Financial highlights

• Revenue for Q1 2026 was $4.5 million, down from $32.7 million in Q1 2025, mainly due to lower milestone and royalty payments and a one-time $6.6 million royalty reduction.

• Operating expenses increased to $82.4 million from $75.9 million year-over-year, with R&D expenses rising by $6.1 million.

• Other expense increased by $45.7 million, primarily due to unrealized losses on marketable equity securities, notably Zenas BioPharma.

• Cash, cash equivalents, and marketable debt securities totaled $541.8 million as of March 31, 2026, down from $610.8 million at year-end 2025.

Outlook and guidance

• Current financial resources are expected to fund operations into mid-2028, assuming current operating plans and potential milestone receipts.

• Expected year-end 2026 cash position between $380 million and $400 million.

• Management expects continued increases in operating expenses as clinical and preclinical programs advance.

• Anticipates key clinical milestones, including interim and primary endpoint analyses for XmAb942 and multiple Phase 1 updates in 2H26.